

Biomechanical Characterisation of Chemoresistant Breast Cancer Cell Lines

Alessia Saponara¹, Valeria Cassina¹, Riccardo Campanile¹, Maria Grazia Cerrito¹, Elisabetta Valeri¹, Francesco Mantegazza¹ and Marina Elena Cazzaniga^{1,2}

¹School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy

²Phase 1 Unit Fondazione IRCCS San Gerardo dei Tintori Monza Italy

a.saponara2@campus.unimib.it

State of the Art


Breast cancer is one of the leading causes of cancer-related mortality worldwide, characterized by molecularly heterogeneous subtypes with distinct biological profiles and clinical outcomes. **CDK4/6 inhibitors** such as **palbociclib** have significantly improved progression-free survival in **hormone receptor-positive (HR+) breast cancer**. However, acquired resistance remains a major clinical challenge that limits long-term therapeutic efficacy. The **mechanical properties** of cancer cells, including stiffness and viscoelastic behavior, are increasingly recognized as **functional hallmarks of tumor biology**, with cytoskeletal alterations linked to tumor aggressiveness, metastatic potential and treatment response.

Aims


Could cell mechanics become a label-free marker of therapy resistance?

This project investigates whether palbociclib resistance in HR+ breast cancer is associated with **biophysical reprogramming**, employing Atomic Force Microscopy (AFM) for high-resolution single-cell **nano-mechanical characterization** alongside complementary molecular analyses to define resistance at both the cellular and biophysical level.



Material & Methods



Atomic Force Microscopy (AFM) Illustration



Young's Modulus E [Pa]




Hertz-Sneddon model, adapted to the pyramidal tip geometry, extraction of the Young's Modulus:

$$F = \frac{E \tan \alpha}{1 - \nu^2} \delta^2 \quad a = \frac{\tan \alpha}{\sqrt{2}} \delta$$

- δ : indentation depth;
- a : radius of the contact circle;
- $\nu = 0.5$: poisson's ratio;

Rheology Experiment



- Approach [nN]
- Pause [nN]
- Modulation [nN]
- Retract [nN]

Parameters:

- A: springpot modulus [Pa]
- B: power-law exponent [-]
- u: newtonian term [Pa·s]
- f_{cross} : crossover frequency [Hz]

Statistics:

- Wilcoxon-Mann-Whitney test,
- p-values * p < 0.05

Resistance model: chronic palbociclib exposure (2 μ M, 6 months) on MCF-7 and T47D

Fractional Kelvin-Voigt Model

$$G'(\omega) = A \cdot \cos(\pi B/2) \cdot \omega^B$$








$$G''(\omega) = A \cdot \sin(\pi B/2) \cdot \omega^B + u \cdot \omega$$

$$\eta(\omega) = \frac{G''(\omega)}{G'(\omega)}$$


- $G'(\omega)$: shear modulus
- $G''(\omega)$: loss modulus
- $\eta(\omega)$: loss tangent

Results of Rheology Experiment

Fit parameters per cell (n=34 cells)



Quantitative Imaging - AFM



Representative **AFM topography images** acquired in **QI-AFM (Quantitative Imaging)** mode of **five breast cell lines**. Cells were seeded on Petri dishes and fixed with 4% paraformaldehyde (PFA) prior to imaging. Scale bar: 20 μ m. Color scale represents surface height (dark = low, bright = high). **QI-imaging settings:** peak force setpoint 60 nN, scan speed 300 μ m/s, z-length 600 nm, resolution 1024 \times 1024 pixels, scan size 100 \times 100 μ m², acquired in air at room temperature using RTESP-300 cantilever (nominal k \approx 40 N/m).

Conclusion

Take-home: Palbociclib resistance leaves a measurable, cell-line-specific fingerprint on cell viscoelasticity, detectable by AFM microrheology.

- HR+ cancer cells (MCF7, T47D) are **softer** than the MCF10A control.
- Resistant variants show **altered cytoplasm-nucleus coupling**, with cell-line-specific crossover shifts.
- The exponent **B** is **modulated upon resistance**, a **reorganization** of the mechanical hierarchy.

Bibliography

- [1] Harbeck, N. et al. (2019). Breast cancer. Nature Reviews Disease Primers, 5, 66.
- [2] Finn, R.S. et al. (2016). Palbociclib and letrozole in advanced breast cancer. New England Journal of Medicine, 375, 1925-1936.
- [3] Watt, A.C. & Goel, S. (2022). Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer. Breast Cancer Research, 24, 17.
- [4] Lekka, M. & Pabijan, J. (2022). Discriminating bladder cancer cells through rheological mechanomarkers. Journal of Biomechanics, 144, 111346.
- [5] Zbiral, B. et al. (2023). Characterization of breast cancer aggressiveness by cell mechanics. International Journal of Molecular Sciences, 24(11), 12208.
- [6] Rigato, A. et al. (2017). High-frequency microrheology reveals cytoskeleton dynamics in living cells. Nature Physics, 13, 771-775